Opko健康 OPK 深 滬

OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference

09-08 17:55

Entera to Participate in Upcoming Fall Investor Conferences

Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in several fall investor conferences in 2026. The company focuses on developing oral peptide therapies for unmet medical needs using its proprietary N-Tab® technology. Its lead product, EB613, an oral PTH(1-34) tablet for osteoporosis, met Phase 2 endpoints. Entera also advances EB612 for hypoparathyroidism and other innovative therapies for obesity and rare conditions.

08-27 12:00

Opko Health Expands Royalty-Backed Long-Term Note Financing

Opko Health ( ($OPK) ) has shared an update. On August 13, 2026, OPKO Health am...

08-15 05:19

OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding

The newly issued notes are secured by OPKO’s royalty interests arising under its mazdutide license agreement with Eli Lilly and Company and mature in 2044, consistent with the maturity of OPKO’s existing HCRx notes issued under the original financing arrangement. The transaction provides OPKO with a...

08-13 21:20

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health expanded its financing with HealthCare Royalty, issuing an additional $125 million in senior secured notes. These notes are backed by mazdutide royalties and mature in 2044. The transaction provides non-dilutive capital while preserving long-term royalty upside. OPKO retains future royalty economics after capped payments of 1.5 times the funded amount. Mazdutide is commercialized in China by Innovent Biologics, with OPKO receiving roy...

08-13 13:15

Entera Q2 2026 earnings: Phase 3 preparation widened the loss

Entera Bio’s Q2 2026 earnings showed no revenue and a net loss of $7.3 million, versus $2.7 million a year earlier, while loss per share widened to $0.14 from $0.06. R&D expense rose to $3.2 million as the company prepared EB613 for a planned late-2026 Phase 3 start and advanced work under its OPKO collaboration. After quarter-end, Entera completed a $275 million private placement that it expects will fund the EB613 registrational program through

08-07 20:18

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Entera Bio Ltd. reported financial results and updates for Q2 2026, highlighting FDA alignment on a 12-month Phase 3 study for EB613, an oral anabolic tablet for postmenopausal osteoporosis. The company secured $275M in private placement led by BVF Partners to fund EB613's development through NDA submission. EB613's Phase 3 initiation is planned for late 2026, with topline data expected in H2 2028. Additionally, preclinical data for EB612, an ora...

08-07 20:05

OPKO Health Boosts Stake in Cocrystal Pharma Financing

Cocrystal Pharma ( ($COCP) ) has shared an announcement. On August 3, 2026, Coc...

08-03 19:48

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Cocrystal Pharma announced a $5 million investment from long-term investor OPKO Health to advance its lead norovirus program toward Phase 1b data expected late in 2026. OPKO acquired 5,474,053 shares at $0.9134 per share. Both companies expressed confidence in Cocrystal's science and pipeline, which includes treatments for influenza, coronaviruses, and hepatitis C.

08-03 11:00

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Ltd. CEO Miranda Toledano will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and available via webcast. Entera, a leader in oral peptide development, is advancing innovative therapies for osteoporosis, hypoparathyroidism, obesity, and rare conditions.

07-31 20:30